Portfolio company
Ancilia Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops CRISPR-engineered bacterial therapies with viral immunity for the biopharmaceutical and healthcare sectors.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Phagos
The company develops AI-powered bacteriophage treatments to combat antibiotic-resistant bacterial diseases, primarily for the animal farming and healthcare sectors.
Hijack Bio
This company develops biotherapeutic drug delivery systems using engineered bacteria to enable the production and delivery of programmable living therapies for pharmaceutical customers.
Ancora Biotech
The company develops multi-specific antibody therapeutics to treat patients with cancer, inflammatory disorders, and chronic hepatitis B infections.
Locus Biosciences
This biotechnology company develops engineered bacteriophage therapies for patients with drug-resistant bacterial infections using CRISPR technology and artificial intelligence.
Kopra Bio
The company develops cancer immunotherapies that engineer cancer cells to produce therapeutic agents for patients, within the deep-tech and digital-health sectors.
AilseBio
This biotech company develops artificial intelligence to discover therapy-induced antigens for cancer vaccines and immunotherapies for the healthcare sector.
Accipiter Biosciences
Accipiter Biosciences develops custom-engineered protein therapies using computational design to treat complex diseases like cancer and autoimmune disorders for the healthcare sector.
MetalloBio
This company develops antimicrobial compounds and medical device coatings to combat antibiotic resistance for the pharmaceutical and healthcare sectors.
